Decoy Therapeutics spotlights a pan-filovirus plan after reporting 1.56 IC50 activity vs. Ebola Zaire
Market Chameleon (Wed, 23-Sep 9:54 AM)
DCOY spotlights FDA Animal Rule strategy and a potential Priority Review Voucher tied to filovirus approvals
Market Chameleon (Tue, 22-Sep 9:52 AM)
DCOY targets FDA Animal Rule path for pan-filovirus program, with PRV value cited at $100–$180 million
Market Chameleon (Tue, 22-Sep 7:50 AM)
